SARS-CoV-2 Serologic Immune Response in Exogenously Immunosuppressed Patients.
J Appl Lab Med
; 6(2): 486-490, 2021 03 01.
Article
in English
| MEDLINE | ID: covidwho-990735
ABSTRACT
BACKGROUND:
While it is presumed that immunosuppressed patients, such as solid organ transplant recipients on immunosuppression, are at greater risk from SARS-CoV-2 infection than the general population, the antibody response to infection in this patient population has not been studied.METHODS:
In this report, we follow the anti-SARS-CoV-2 antibody levels in patients with COVID-19 who are undergoing exogenous immunosuppression. Specifically, we studied the antibody response of 3 solid organ transplant recipient patients, 3 patients who take daily inhaled fluticasone, and a patient on etanercept and daily inhaled fluticasone, and compared them to 5 patients not on exogenous immunosuppression.RESULTS:
We found that the solid organ transplant patients on full immunosuppression are at risk of having a delayed antibody response and poor outcome. We did not find evidence that inhaled steroids or etanercept predispose patients to delayed immune response to SARS-CoV-2.CONCLUSION:
The data presented here suggest that solid organ transplant recipients may be good candidates for early targeted intervention against SARS-CoV-2.
Full text:
Available
Collection:
International databases
Database:
MEDLINE
Main subject:
Immunocompromised Host
/
SARS-CoV-2
/
COVID-19
/
Immunosuppressive Agents
/
Antibodies, Viral
Type of study:
Diagnostic study
/
Prognostic study
Limits:
Adult
/
Aged
/
Female
/
Humans
/
Male
/
Middle aged
/
Young adult
Language:
English
Journal:
J Appl Lab Med
Year:
2021
Document Type:
Article
Affiliation country:
Jalm
Similar
MEDLINE
...
LILACS
LIS